Leasing Success in Zurich: ACRON extends lease with second main tenant Baxter in “Portikon” Office Building to end of 2025
At the end of December 2018, real estate investment specialists the ACRON Group extended the lease with Baxter Healthcare S.A. for approximately 4,200 m2 of office space to end 2025 on behalf of ACRON Swiss Premium Assets AG (ASPA). After the lease extension with Takeda Pharmaceuticals International AG until 2024 last year, the office building remains occupied with its two prominent tenants.
The Portikon building is directly owned by ACRON Swiss Premium Assets AG (ASPA), which is still open to investment exclusively by qualified investors in Switzerland under the original terms. This offers investors an attractive opportunity to participate in a Swiss commercial real estate investment.
The contract extension confirms Baxter's excellent location conditions for its activities in Switzerland. Baxter International is a US-based global pharmaceutical and medical device company. It employs more than 50,000 people in more than 100 countries worldwide. The Portikon building, which meets the Minergie-P® standard, features a spacious lobby, a centrally located, light-filled atrium, and various conference and meeting rooms. A restaurant in the building is available to employees and visitors.
The Glattpark neighborhood is situated in the town of Opfikon in the prosperous Glattal region. Opfikon is part of the vibrant and sophisticated Zurich metropolitan area. The quarter is located between Zurich-Kloten Airport and Zurich, known for its old town center and lake. Opfikon’s proximity to the airport and the lively city of Zurich is the engine for the town’s economic activity.
“The lease extension with our prominent anchor tenant Baxter Healthcare confirms both the quality and the location of Portikon as a prime asset”, says Peer Bender, CEO of ACRON AG.
ACRON Swiss Premium Assets AG was advised by CBRE Switzerland.
At the end of December 2018, real estate investment specialists the ACRON Group extended the lease with Baxter Healthcare S.A. for approximately 4,200 m2 of office space to end 2025 on behalf of ACRON Swiss Premium Assets AG (ASPA). After the lease extension with Takeda Pharmaceuticals International AG until 2024 last year, the office building remains occupied with its two prominent tenants.
The Portikon building is directly owned by ACRON Swiss Premium Assets AG (ASPA), which is still open to investment exclusively by qualified investors in Switzerland under the original terms. This offers investors an attractive opportunity to participate in a Swiss commercial real estate investment.
The contract extension confirms Baxter's excellent location conditions for its activities in Switzerland. Baxter International is a US-based global pharmaceutical and medical device company. It employs more than 50,000 people in more than 100 countries worldwide. The Portikon building, which meets the Minergie-P® standard, features a spacious lobby, a centrally located, light-filled atrium, and various conference and meeting rooms. A restaurant in the building is available to employees and visitors.
The Glattpark neighborhood is situated in the town of Opfikon in the prosperous Glattal region. Opfikon is part of the vibrant and sophisticated Zurich metropolitan area. The quarter is located between Zurich-Kloten Airport and Zurich, known for its old town center and lake. Opfikon’s proximity to the airport and the lively city of Zurich is the engine for the town’s economic activity.
“The lease extension with our prominent anchor tenant Baxter Healthcare confirms both the quality and the location of Portikon as a prime asset”, says Peer Bender, CEO of ACRON AG.
ACRON Swiss Premium Assets AG was advised by CBRE Switzerland.
Edmond de Rothschild Real Estate: plus besoin d’augmenter le capital de la SICAV suisse